Stockwinners Market Radar for September 29, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:46 EDT Cathie Wood's ARK Investment bought 951K shares of UiPath today

19:50 EDT Citrix trading halted, news pending

19:25 EDT MoneyLion issues response to Consumer Financial Protection Bureau - The company states: "MoneyLion has cooperated in good faith with the CFPB for over three years regarding our membership offering. Our innovative membership program helps service members and other customers save, invest, build credit and improve their overall financial lives. Despite our cooperation, the Bureau has chosen the sensationalist route of prioritizing headlines instead of engaging in constructive dialogue to address their questions and to achieve better consumer outcomes. We will vigorously defend against these false allegations to set the record straight as we continue to deliver innovative financial products that help our customers. The claims made by the Bureau about our membership offering, a product that represents a small subset of MoneyLion's business, are without merit. MoneyLion has the highest regard for its military and veteran customers and are committed to working with this important community to help them achieve better financial health."

18:56 EDT AVCtechnologies intends to effect a 1-for-15 reverse stock split - American Virtual Cloud Technologies announces that it intends to effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock. The Reverse Stock Split will become effective on September 30, 2022 upon filing with the Delaware Secretary of State of an amendment to the company's amended and restated certificate of incorporation, and the company's common stock is expected to begin trading on a split-adjusted basis when the market opens on October 3, 2022. The company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "AVCT." The new CUSIP number for the common stock following the Reverse Stock Split will be 030382204.

18:33 EDT Morgan Stanley CEO: Unlikely we will have a hard landing - In an interview on CNBC's Mad Money, James Gorman said it's not totally surprising where we are today. "You can't have free money forever," he added. He feels inflation, unemployment, and interest rates all at 4% would be an ideal situation. There are reasons to be concerned, he said, but he hasn't seen enough yet to say it's a full blow crisis. The company is dealing with 15M clients and not seeing panic. U.S. banks are in the best shape financially in decades, he noted. Gorman feels "very good" about the company's financial position as it expects to retire 6%-7% of stock this year and offers a 3.5% dividend.

18:04 EDT Rent-A-Center sinks 18% after cutting Q3 guidance, naming new CFO

17:52 EDT United Natural Foods increasing investment in Shoppers banner - United Natural Foods is reacquiring three former store locations which had previously been sold and remodeling two existing store locations, as part of its commitment to build its Shoppers banner by adding to and improving the stores in its portfolio. In addition to the three new locations in Maryland, Shoppers is scheduled to complete in early October remodels at their stores in Forestville, Md.

17:40 EDT Nike CFO says FY23 gross margins to decline 200-250bps in FY23 - Sees negative FX headwind at about $4B.

17:33 EDT Miniso's Chairman of the Board to purchase up to $5M in shares - Miniso's Chairman of the Board of directors, CEO and the controlling shareholder of the company, Guofu Ye, has informed the company of his intention to use his personal funds to purchase up to an aggregate of $5M worth of the company's ordinary shares and/or ADS, representing approximately 0.3% of the total issued share capital of the company based on the ADS closing price as of September 28, within the next twelve months. At this date, Ye is interested in approximately 61.6% of the total issued shares of the company through entities controlled by him and/or his spouse.

17:28 EDT Nike extends decline, down over 9% afterhours - Shares of Nike are now down 9.4% afterhours at $86.35 following conference call comments that company is taking action to clear inventory.

17:22 EDT Nike CEO says these are times when strong brands get stronger - Says confident in ability to extend and expand market lead. Comments taken from Q1 earnings conference call.

17:15 EDT FDA grants approval of Relyvrio to treat ALS patients to Amylyx - The FDA approved Relyvrio to treat patients with amyotrophic lateral sclerosis, or ALS, commonly referred to as Lou Gehrig's disease. The FDA granted this application Priority Review designation. It also received orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. The FDA granted the approval of Relyvrio to Amylyx. "This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure," said Billy Dunn, M.D., director of the Office of Neuroscience in the FDA's Center for Drug Evaluation and Research. "The FDA remains committed to facilitating the development of additional ALS treatments."

17:09 EDT Lockheed Martin awarded $272.98M Army contract modification - Lockheed Martin was awarded a $272.98M modification to a contract for services, hardware, facilities, equipment, and all technical, planning, management, manufacturing, and testing efforts to produce Phased Array Tracking Radar to Intercept on Target Advanced Capability-3 missiles. Work has an estimated completion date of December 31, 2027. FY22 missile procurement, Army and fiscal 2022 Foreign Military Sales funds in the amount of $133.76Mwere obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:01 EDT Rent-A-Center names Fahmi Karam CFO - Rent-A-Center (RCII) announced that Fahmi Karam, currently Chief Financial Officer of Santander Consumer USA (SAN), will join the company as Executive Vice President - Chief Financial Officer effective October 31, 2022. The company also announced that its current Executive Vice President - Chief Financial Officer, Maureen Short, departed the company on September 28, 2022. Karam has over 20 years of experience in finance and accounting, most recently as the Chief Financial Officer of Santander Consumer USA since September 2019. Karam previously served as Santander's Head of Pricing and Analytics from May 2018 to September 2019 and as Executive Vice President, Strategy and Corporate Development from September 2015 to May 2018. "Fahmi's extensive experience and leadership in finance and strategic initiatives, including in the consumer finance industry, will be a valuable addition to our executive team as we continue to position our company for growth opportunities," said Mitch Fadel, Chief Executive Officer of Rent-A-Center. "We are excited to have Fahmi join our leadership team and look forward to his insights and contributions to our company. I would also like to thank Maureen for her many years of service and contributions to the company, and we wish her the best in her future endeavors."

16:46 EDT Scorpio Tankers purchases 225,000 of its common shares in the open market - On September 29, the company purchased 225,000 of its common shares in the open market at an average price of $40.80 per share as part of the company's securities repurchase program.

16:44 EDT Chevron, FreeWire Technologies partner on EV charging equipment, solutions - FreeWire Technologies announced a program to make available battery-integrated electric vehicle charging equipment and solutions for Chevron's branded stations. This will include both Chevron's company-owned stations as well as its independently owned retailer and marketer stations. FreeWire's program will provide an integrated approach by coupling battery-integrated chargers supported by energy management software with custom branding/design and analytics. FreeWire's fully integrated Boost Charger will allow customers to get 200 miles of range in 15 minutes. The Boost Charger plugs into existing low-voltage utility service and delivers high-power charging that typically requires extensive site improvements and grid upgrades.

16:43 EDT Comscore to reduce workforce, sees $13M-$18M in related costs - In an 8-K filing, the company states: "On September 29, 2022, comScore communicated a workforce reduction as part of its broader efforts to improve cost efficiency and better align its operating structure and resources with strategic priorities. In addition to employee terminations, the Restructuring Plan is expected to include the reallocation of commercial and product development resources; reinvestment in and modernization of key technology platforms; consolidation of data storage and processing activities to reduce the Company's data center footprint; and reduction of other operating expenses, including software and facility costs. The Company may also determine to exit certain activities in certain geographic regions in order to more effectively align resources with business priorities. In connection with the Restructuring Plan, which was authorized by the Company's Board of Directors on September 19, 2022, the Company will incur certain exit-related costs. These costs are currently estimated to range between $13M and $18M."

16:41 EDT Micron says will soon announce a second high-volume U.S. DRAM manufacturing site - Says new fabs will fulfill requirements for additional wafer capacity starting in the second half of the decade and beyond.

16:37 EDT Vanda Pharmaceuticals and OliPas partner to develop antisense oligonucleotides - Vanda Pharmaceuticals and OliPass have entered into a research and development collaboration agreement to jointly develop a set of antisense oligonucleotide - ASO - molecules based on OliPass' proprietary modified peptide nucleic acids. The collaboration will focus on editing and modifying gene expression using ASOs in disease states where the expression of genes is either altered or the sequence of the expressed genes can be altered for therapeutic benefit. Vanda has already identified two ASO targets that have been validated in cell lines that model two undisclosed disease targets.

16:35 EDT Nike reports inventories in Q1 up 44% y/y, gross margins down 220bps - The company states: "Inventories for NIKE, Inc. were $9.7 billion, up 44 percent compared to the prior year period, driven by elevated in-transit inventories from ongoing supply chain volatility, partially offset by strong consumer demand during the quarter... Gross margin decreased 220 basis points to 44.3 percent, primarily driven by elevated freight and logistics costs, lower margins in our NIKE Direct business driven by higher markdowns, and unfavorable changes in net foreign currency exchange rates, including hedges, partially offset by strategic pricing actions. The overall decrease in margins was primarily driven by North America, which took measures to liquidate excess inventory through NIKE Direct markdowns and wholesale marketplace actions."

16:31 EDT Micron says modeling lowest-ever DRAM industry supply growth in 2023 - Says expects the inventory at our customers to improve in early calendar 2023, causing demand to rebound starting from the second quarter of calendar 2023. Says expects calendar 2023 industry DRAM supply to grow well below demand growth. Says modeling a mid-single-digit percentage growth in DRAM industry supply in 2023, which would represent the lowest-ever industry supply growth. Says NAND supply growth in calendar 2023 is also expected to fall below demand growth.

16:30 EDT Fannie Mae names Priscilla Almodovar as CEO - Fannie Mae announced that it has appointed Priscilla Almodovar as CEO and member of the Board of Directors, effective December 5, 2022. Almodovar will succeed David Benson, who has served as Interim CEO and a member of the Board of Directors since May 2022. After her arrival, Benson will continue in his role as President. Almodovar brings more than 30 years of experience in finance, real estate, and community development across a number of institutions and organizations. Since 2019, she has served as President and CEO of Enterprise Community Partners, a national organization focused on increasing the supply of affordable housing, advancing racial equity, and supporting residents and communities.

16:29 EDT Summit Healthcare Acquisition to merge with YS Biopharma - YishengBio, to be renamed as YS Biopharma Co., and Summit Healthcare Acquisition Corp. announced that they have entered into a definitive agreement for a business combination of Summit and the company. Upon closing of the transaction, the combined company will be renamed as YS Biopharma and become a publicly traded company on the Nasdaq. Upon closing of the transaction, YS Biopharma will continue to be led by Mr. Yi Zhang, its founder and chairman, Dr. Hui Shao, its president and chief executive officer, and the current management team. YS Biopharma has over 800 employees with business operations in China, Singapore, the United States, the United Arab Emirates and the Philippines. The pre-money equity value of YS Biopharma in the proposed transaction is approximately $834M. YS Biopharma shareholders will become the majority owners immediately after the closing of the transaction. The business combination is expected to provide up to approximately $230M in gross proceeds to YS Biopharma, including $30M from Forward Purchase Investors and up to approximately $200M currently held in Summit's trust account, assuming no redemption from Summit's existing public shareholders. "Proceeds from the transaction will allow YS Biopharma to fund its ongoing and planned clinical trials, future commercial launch of PIKA adjuvanted rabies vaccine, the construction of new GMP-compliant manufacturing plants as well as developing other product candidates," the company said. The transaction is targeted to be completed in the first quarter of 2023.

16:28 EDT Invacare receives notice of noncompliance with NYSE share price listing rule - Invacare Corporation announced that it received notice from the New York Stock Exchange that the company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's Common Shares was less than $1.00 per share over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the company's Common Shares from the NYSE. The company plans to notify the NYSE by October 7, 2022 that the company intends to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. The company can regain compliance at any time within the six-month period following receipt of the NYSE notice if on the last trading day of any calendar month during the six-month period the company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to shareholder approval no later than at the company's next annual meeting of shareholders, if necessary to cure the stock price non-compliance. Under the NYSE's rules, if the company determines that it will cure the stock price deficiency by taking an action that will require shareholder approval at its next annual meeting of shareholders, the price condition will be deemed cured if the price promptly exceeds $1.00 per share, and the price remains above that level for at least the following 30 trading days.

16:25 EDT Micron says cutting FY23 capital expenditures - Says Q4 financial results were impacted by rapidly weakening consumer demand and significant customer inventory adjustments across all end markets. Says share gains in client and data center SSDs contributed to record revenue in SSDs and also in consolidated NAND business. Says decreasing supply growth through significant cuts to fiscal 2023 capital expenditures and by reducing utilization in fabs. Says remains on track to begin the ramp of its 1-beta DRAM node in manufacturing by the end of calendar 2022. Says both the 1-beta DRAM node and 232-layer NAND node will provide the company with robust cost reduction when they ramp in high volume. Comments taken from Q4 prepared remarks.

16:19 EDT Nike slips 2% to $93.27 after Q1 results

16:16 EDT Genfit signs share repurchase agreement, completes Versantis acquisition - Genfit announced the signing of the share purchase agreement and the completion of its acquisition of Versantis AG under the terms announced in its press release on September 19. As a result of this acquisition, Genfit consolidates its position in Acute on Chronic Liver Failure, or ACLF, via the integration of a clinically advanced asset presenting a solid scientific rationale supported by encouraging Phase 1b and preclinical data. Genfit will also further expand its pipeline in other liver diseases characterized by high unmet medical needs with additional product candidates developed by Versantis.

16:11 EDT Xos delivers 13 battery-electric stepvans to four FedEx Ground Operators - Xos (XOS) announced it has delivered 13 of its 100% battery-electric stepvans to four FedEx (FDX) Ground Operators across four states. The FedEx Ground Operators include RNR Transport Inc. in Olathe, Kanas, Sisa Inc. in Pacoima, California, Hidden Arrow Inc. in Niles, Illinois and Limestone Logistics in Independence, Kemtucky.

16:09 EDT Fluor says DOE extends SRNS management, operating contract - Fluor announced that the U.S. Department of Energy has extended the Fluor-led Savannah River Nuclear Solutions, LLC management and operating contract at the Savannah River Site near Aiken, South Carolina. The extension includes 4 years with an additional 1-year option. The total reimbursable contract value is $12B for 5 years, and Fluor will book its 4-year, $4.5B portion in the third quarter. SRNS will continue uninterrupted management and operations activities at the site. "This extension represents the DOE's confidence in our performance to help safeguard our nation's security and deliver on the important mission at the site," said Tom D'Agostino, group president of Fluor's Mission Solutions business. "We are continually improving efficiencies to accelerate program objectives and lower costs while also delivering capital projects of every scale. Our success is the result of a constant focus on the safety and security of our workers and protecting the surrounding communities and the environment."

16:07 EDT Vertex Energy cuts Q3 throughput volumes to 68K-69K bpd from 72K-74K - Vertex Energy provided an update to its operational and financial outlook for the company's Mobile, Alabama Refinery. Throughput volumes for the third quarter of 2022 are now estimated to be approximately 68,000-69,000 barrels per day. The reduced estimated throughput volumes for the quarter, versus the Company's previously communicated guidance, reflect management's decision to accelerate significant planned maintenance following recent and temporary crude supply issues. These supply issues resulted from third-party disruptions, impacting Vertex's supplier's ability to fulfill its contracted supply mandate for water-borne crude oil. Including the impact of these updates, operating expense per barrel for the third quarter of 2022 is estimated to be approximately $4.25 - $4.50 per barrel, capture rate on the benchmark Gulf Coast 2-1-1 crack spread is anticipated to remain at 50%-54%, and total capital expenditures are estimated to remain at $30 - $35 million, for the third quarter of 2022, as previously communicated.

16:07 EDT Computer Task Group acquires Eleviant Tech, terms undisclosed - CTG announced that it has acquired Eleviant Tech, a privately owned digital transformation company with expertise in mobile, cloud, web, blockchain, robotic process automatio and artificial intelligence technologies. Headquartered in Dallas, Texas, Eleviant helps clients in manufacturing, logistics, healthcare, finance, and insurance industries. The acquisition is expected to add approximately $10M in annualized revenue; expected to be immediately accretive to operating results, excluding customary acquisition-related expenses.

16:05 EDT BioMarin submits BLA to FDA for valoctocogene roxaparvovec - BioMarin Pharmaceutical announced that the company resubmitted a Biologics License Application to the U.S. FDA for its investigational AAV gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. The resubmission incorporates the company's response to the FDA Complete Response Letter for valoctocogene roxaparvovec gene therapy issued on August 18, 2020, and subsequent feedback, including two-year outcomes from the global GENEr8-1 Phase 3 study and supportive data from five years of follow-up from the ongoing Phase 1/2 dose escalation study.

16:03 EDT M&T Bank to sell M&T Insurance Agency to Arthur J. Gallagher, no terms - M&T Bank (MTB) announced that it has signed a definitive agreement to sell M&T Insurance Agency to Arthur J. Gallagher & Co. (AJG). The transaction is subject to regulatory approval and is expected to close during the fourth quarter of this year. Terms of the sale were not disclosed.

15:25 EDT Merck says appeals court rules in company's favor on sitagliptin patent - Merck (MRK) announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, now Viatris (VTRS), related to sitagliptin dihydrogen phosphate, an active ingredient in Januvia, Janumet, and Janumet XR. Viatris had challenged validity of U.S. Patent No.7,326,708 in an inter partes review before the U.S. Patent Office. On May 7, 2021, the Patent Office issued a decision in Merck's favor, finding all challenged claims valid. Viatris appealed that decision to the Court of Appeals for the Federal Circuit, which today affirmed the decision. Viatris had previously challenged validity of the patent in a case filed in the U.S. District Court for the Northern District of West Virginia. The District Court ruled in favor of Merck in a decision dated Sept. 21, 2022. "Today's ruling from the U.S. Court of Appeals provides Januvia, Janumet, and Janumet XR patent protection through May 2027, which includes six months of pediatric exclusivity. The company has settled with multiple generic companies, providing that these generic companies can bring their sitagliptin dihydrogen phosphate or sitagliptin-metformin product to the market in May 2026 or earlier under certain circumstances, and their sitagliptin-metformin extended-release product to the market in July 2026 or earlier under certain circumstances," Merck stated.

14:42 EDT Alisa Bowen named President Of Disney+ - Alisa Bowen has been named President of Disney+, effective immediately, Disney announced. Bowen most recently served as EVP of Global Business Operations for Disney Streaming, overseeing global content and business operations for the company's direct-to-consumer video streaming businesses, Disney+, Hulu, ESPN+, and Star+. "In this role, Bowen will build on the flagship streaming service's reputation as a global destination for premium content. Bowen has led global business operations for Disney's streaming platforms, including Disney+, since its launch in 2019. In that time, Disney+ has expanded rapidly, growing its reach to 154 markets worldwide with 152.1 million total subscriptions as of the end of the third quarter in fiscal year 2022. Bowen will work closely with key leaders across The Walt Disney Company to drive continued focus on innovation, including the forthcoming launch of the advertising-supported tier, as well as multi-channel promotional support for Disney+ and its robust content slate," Disney stated. Reference Link

13:44 EDT PepsiCo offering buyouts to employees 55+, Fox Business' Gasparino says - Fox Business' Charles Gasparino said in a tweet that, "SCOOP: Sources tell @FoxBusiness @PepsiCo is in cost cutting mode as economy starts to turn south and is offering buyouts to employees 55+. People inside co say layoffs loom if biz conditions continue to deteriorate." Reference Link

13:30 EDT Arcimoto trading resumes

13:06 EDT Orchid Island Capital alerts stockholders to dividend payment issue - Orchid Island Capital has become aware of an issue with stockholders of record of the company's common stock on August 31, 2022 not receiving the full monthly cash dividend for the month of August 2022 of 16c per share that should have been paid on September 28, 2022. The company fully funded this 16c per share dividend by making payment to its transfer agent prior to September 28, 2022. The company understands that an inadvertent administrative error at DTC resulted in brokers not receiving the full amount of the dividend. The company is working to resolve this issue as soon as possible.

13:02 EDT Illumina unveils NovaSeq X Series sequencers - Illumina announced the launch of the NovaSeq X Series - NovaSeq X and NovaSeq X Plus - which it calls "new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing." Illumina said: "Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year - 2.5 times the throughput of prior sequencers - greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives." Francis deSouza, Illumina's CEO, added: "Innovations like NovaSeq X are at the heart of how we will transform patient lives, and this groundbreaking technology will empower researchers, scientists, and clinicians in the fight to diagnose, treat - and eventually cure - disease while making genomics more sustainable and accessible to millions more people around the world." More information on NovaSeq X Series sequencers is available [here.]:[https?://illumina.com/novaseqx]

13:01 EDT Arcimoto announces restructuring, anticipates 32% reduction in payroll expenses - Arcimoto announced a strategic restructuring with the goal to focus operations on immediate revenue-driving programs such as FUV consumer sales, Deliverator fleet sales, and rentals in key markets. As a result, the company anticipates a 32% reduction in payroll expenses, through a combination of temporary furloughs and permanent workforce reductions and is reducing operational expenses through budget realignment across the company. The plan is designed to support the company's growth and profitability objectives and improve its operating margin. "Today's cost restructuring is a direct response to the macroeconomic environment conditions and supply chain issues we are facing, requiring us to be more disciplined and laser focused on the areas of our business that are most critical to achieving profitability," said Interim CEO Jesse Fittipaldi. "Operating with greater efficiency and focusing on the parts of our business that are most critical to achieving profitability will allow us to deliver more vehicles to happy customers. We do not take these actions lightly; we love our Team, but these difficult steps are necessary in order to maximize our current resources, reduce operating expenses across the board, and generate increased value for our shareholders." Some long-term projects have been put on hold for the immediate future. This will allow the Company to focus on improvements to the FUV, Deliverator, and Flatbed, the core products that are driving consumer sales and rentals, as well as fleet sales, respectively.

12:25 EDT JPMorgan senior debt ratings upgraded by Moody's - Moody's Investors Service upgraded to A1 from A2 the issuer and senior debt ratings of JPMorgan Chase and the senior debt ratings of JPM's guaranteed subsidiary. All other ratings of JPMorgan were affirmed, and the ratings outlook for the bank is stable. The upgrade of JPM's senior debt to A1 "reflects Moody's assessment that the recently increased levels of holding company debt outstanding relative to JPM's total assets will be sustained."

12:00 EDT Altus Power falls -23.5% - Altus Power is down -23.5%, or -$3.34 to $10.88.

12:00 EDT Rite Aid falls -27.9% - Rite Aid is down -27.9%, or -$1.96 to $5.07.

12:00 EDT Daily S&P Biotech Bear 3x Shares rises 9.7% - Daily S&P Biotech Bear 3x Shares is up 9.7%, or $2.19 to $24.67.

11:36 EDT Tesla CEO says Cybertruck can serve as boat, cross rivers - Tesla CEO Elon Musk said via Twitter, "Cybertruck will be waterproof enough to serve briefly as a boat, so it can cross rivers, lakes & even seas that aren't too choppy."

11:28 EDT WestJet reaches deal with Boeing to purchase additional 42 MAX jets - WestJet Group, a subsidiary of Onex Corporation (ONEXF), announced an agreement with Boeing (BA) to purchase an additional 42 MAX aircraft, along with options for 22 more. This order is in addition to WestJet's remaining 23 MAX orders and extends the airline's fleet growth plans out to 2028. "With this additional order, the WestJet Group will accept delivery of no fewer than 65 aircraft in the next six years, at least 50 will be 737-10 aircraft, furthering our commitment to affordable travel options for Canadians and jobs for our company and the aerospace industry," said WestJet Group Chief Executive Officer Alexis von Hoensbroech. "WestJet's expansion plans are rooted in an enhanced presence in Western Canada and a growth strategy in eastern Canadian communities through increased transcontinental flights and more direct routes to sun and leisure destinations. This will be further strengthened once our Sunwing transaction has been approved." WestJet's Board of Directors approved the order for state-of-the-art Boeing 737-10 aircraft, the largest model in Boeing's MAX family. The 737-10 provides superior economic benefits to any other 737 aircraft in WestJet's fleet, while ensuring simplicity through expected training commonality across the airline's 737 fleet.

11:22 EDT DXC Technology up 8% after report says takeover price near $45 discussed - Shares of DXC Technology are up $1.86, or 8%, to $25.94 after resuming trading following a report from Street Insider that claims that the takeover price being discussed for DXC is around $45 per share.

11:20 EDT Catalyst Pharmaceuticals announces FDA approval of sNDA for FIRDAPSE - Catalyst Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application to expand the indicated age range for FIRDAPSE Tablets 10 mg to include pediatric patients, six years of age and older for the treatment of Lambert-Eaton myasthenic syndrome. FIRDAPSE is currently approved in the U.S. and Canada for the treatment of LEMS in adult patients.

11:13 EDT Pokemoto signs two franchise agreements in South Carolina - Pokemoto announced its entry into South Carolina by signing two new franchise agreements in the Palmetto State. The two new agreements signify the 45th and 46th agreements signed for the expanding Hawaiian Poke chain. Entering South Carolina will add another state to the brand's roster bringing its total count to 14 states when looking at open and coming soon Pokemoto locations.The agreements focus on the Myrtle Beach and Carolina Forest markets.

11:06 EDT Atos confirms ICG offered to buy Evidian, says deal not in interest of company - Atos issued the following statement: "Following a market rumor, Atos confirms that on Tuesday, September 27, the Group received an unsolicited letter of intent from onepoint, in association with the British private equity fund ICG, related to the potential acquisition of the 'Evidian' perimeter, for an indicative enterprise value of EUR 4.2 billion. Following the thorough examination of this preliminary and non-binding mark of interest, and upon the recommendation of its ad hoc committee, the board of directors has convened and unanimously concluded that it is not in the interest of the company and its stakeholders. The board of directors has therefore decided not to proceed." Reference Link

11:03 EDT Neurocrine appoints Ingrid Delaet as CRO - Neurocrine Biosciences (NBIX) announced that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.Prior to joining Neurocrine Biosciences, Dr. Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals (ICPT), which she joined in 2016.

11:02 EDT AMV Stock trading resumes

10:54 EDT Senators Warren, Jones ask FTC to block Amazon from buying iRobot

10:18 EDT PPL Corp. to sell Safari Holdings, terms not disclosed - PPL Corporation has reached an agreement to sell PPL Safari Holdings, parent company of Safari Energy, a subsidiary that acquires solar projects and develops and manages solar facilities for commercial and industrial customers and public sector organizations. A subsidiary of Aspen Power Partners LLC has agreed to acquire PPL Safari pending review by the U.S. Department of Justice. PPL's decision to sell Safari reflects the company's recent strategic repositioning as it sharpens its focus on its core business, high-performing regulated utilities in the U.S., and on advancing the clean energy transition through forward-looking grid investments and the continued transition of the company's Kentucky generation fleet. PPL and Aspen expect to close on the transaction in the fourth quarter of 2022. The sale is not considered material to PPL Corporation.

10:04 EDT Norfolk Southern creates Transportation, Network Operations organization - Norfolk Southern Corporation has created a combined Transportation and Network Operations organization led by Paul Duncan. Duncan has been promoted to Senior Vice President Transportation and Network Operations and will lead the team responsible for designing network operations, executing network plans, and coordinating the movement of trains across the company's rail network. Duncan previously led Network Planning & Optimization and the Network Operations Center. The two teams are responsible for developing and implementing Norfolk Southern's operating plan. The addition of the Transportation Department, under the leadership of Vice President Transportation Floyd Hudson, will bring together and strengthen all the Operations groups responsible for service improvement and quality.

10:00 EDT Altus Power falls -17.9% - Altus Power is down -17.9%, or -$2.54 to $11.69.

10:00 EDT Rite Aid falls -22.5% - Rite Aid is down -22.5%, or -$1.58 to $5.45.

10:00 EDT Small Cap Bear 3x rises 8.6% - Small Cap Bear 3x is up 8.6%, or $3.64 to $45.83.

09:50 EDT SilverSun Technologies trading resumes

09:47 EDT Rite Aid falls -18.6% - Rite Aid is down -18.6%, or -$1.31 to $5.72.

09:47 EDT Enerpac Tool rises 5.2% - Enerpac Tool is up 5.2%, or 88c to $17.67.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas rises 6.8% - ProShares UltraShort Bloomberg Natural Gas is up 6.8%, or $1.10 to $17.34.

09:35 EDT Allegiant says Ian to bring down revenue guide by 1.5 percentage points - Drew Wells, senior vice president, revenue, at Allegiant said: "We finished August with a nearly two-point improvement in loads as compared with August of 2019, on 14.6 percent more capacity. We were on track to come in above our revenue guide of up 29 percent, year over three-year. However, the impacts from Hurricane Ian have resulted in the cancellation of the majority of our flights touching Florida over the course of the next few days. Although the situation is still developing, we believe the impacts from Ian will bring down our revenue guide by 1.5 percentage points."

09:30 EDT Simplicity Esports signs exchange agreement with River Technology - Simplicity Esports and Gaming Company has entered into an exchange agreement with Diverted River Technology, pursuant to which Simplicity Esports agreed to acquire 100% of the membership interests of Diverted River in exchange for 80% of the issued and outstanding shares of Simplicity Esports' common stock. Following the closing, it is expected that, Simplicity Esports' name will be changed to Diverted River Technology, Inc., and the business of Simplicity Esports will become that of Diverted River, an ETO focused on a sustainable, high margin, recurring revenue business model that requires limited capital expenditures. It is also expected that Mr. Johnson, Diverted River's CEO, will become CEO of the public company following the closing. The transaction, which is expected to close prior to year end, is subject to standard closing conditions, including the repayment of certain debts and achieving a minimum amount of working capital.

09:26 EDT Sunrise New Energy announces RMB 19M order from Pylon - Sunrise New Energy announced a new customer win with an initial RMB19M order from Pylon Technologies Co., Ltd. The order is for Sunrise's graphite anode. It is a validation order to establish the relationship. Both companies expect the business to expand substantially over time.

09:25 EDT Aditx Therapeutics regains compliance with Nasdaq - Aditxt announces it has received confirmation from Nasdaq Stock Market Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, meets the stockholders' equity requirement in Nasdaq Listing Rule 5550 and meets all other applicable criteria for continued listing. Aditxt recently completed a reverse stock split and closed a $20M public offering. Amro Albanna, co-founder, chairman and CEO of Aditxt, said both events were key to the company's successful Nasdaq compliance and continued progress within each of the company's programs toward commercialization, which currently include AditxtScore, Adimune and Adivir.

09:18 EDT Meritage Homes releases second annual ESG report - Meritage Homes announced the release of its second annual Environmental, Social and Governance, ESG, report. The comprehensive review of 2021 covers the Company's sustainability and governance practices, diversity, equity and inclusion efforts, and milestones achieved during the year. Building off last year's inaugural greenhouse gas emissions inventory, Meritage is the first U.S. public production builder to issue a Task Force on Climate-Related Financial Disclosures report, which outlines the Company's climate risks and opportunities. "Responsible corporate citizenry is paramount at Meritage. By embedding sustainability and DE&I into our strategy and operations, we look to maintain our position as an industry leader in ESG and continue to deliver long-term value to all stakeholders," said Phillippe Lord, Chief Executive Officer of Meritage Homes. "There is no finish line when it comes to ESG, and our commitment to these efforts is evergreen. There is still much work to be done, but our team is excited to continue doing what we do best: delivering our brand promise of a Life. Built. Better."

09:17 EDT NRC Health announces sponsorship of Creative Learning Event Series - NRC Health announced its sponsorship of the upcoming Creative Learning Event Series hosted by the Society for Participatory Medicine. The year-long, four-part series aims to empower and embolden patients, healthcare professionals, and caregivers to create a more equitable healthcare environment.

09:15 EDT Panbela receives regulatory approval for opening trial sites for ASPIRE trial - Panbela Therapeutics announced Regulatory approval for the opening of trial sites in Spain, France and Italy for Panbela's clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. With approximately 95 sites planned throughout the United States, Europe, Australia, and South Korea, the company is continuing to focus on site initiation and enrollment in order to ultimately deliver a more effective treatment for pancreatic cancer, a deadly disease with few treatment options. Panbela expects that a significant number of global sites will be open by year-end with the full complement of sites open by the first quarter 2023. "We're excited to have these recent approvals as we move forward towards the interim analysis which is expected to be completed in early 2024," commented Jennifer Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.

09:14 EDT Jamf Holding publishes inaugural purpose & impact report - Jamf published its first Purpose and Impact Report, highlighting its long-standing commitment to empowering people and the communities in which it operates through technology. The report, which formalizes the company's dedication to tracking and reporting environmental, social, and governance initiatives, includes summaries and performance metrics demonstrating its purpose-driven culture and devotion to responsible business practices. "Since we began operations two decades ago, Jamf has had a passion for empowering people by simplifying work and helping communities to thrive," said Dean Hager, Chief Executive Officer at Jamf. "As we continue to expand our business, we are committed to being a company where our employees can continue bringing their full self to work, customers can continue relying on our services, communities can keep growing with us, and the environment does not get overly burdened by our operations. By providing a window into our ongoing actions and a foundation for further progress, our first Purpose and Impact Report is a pivotal step toward this commitment."

09:11 EDT Acasti Pharma announces voting results from Annual General, Special Meeting - Acasti Pharma announced the voting results from its Annual General and Special Meeting of Shareholders which was held virtually on Wednesday September 28, 2022. All five nominees listed in the proxy statement dated August 31, 2022, being Jean Marie Canan, Jan D'Alvise, Donald Olds, Vimal Kavuru and Michael L. Derby were elected as directors of Acasti at the Meeting to serve for a term that expires at the 2023 annual meeting of Acasti shareholders or until their successors are duly elected or appointed, unless such office is earlier vacated in accordance with Acasti's by-laws. The Company thanks Dr. Roderick Carter for his board service and chairmanship over the last 7 years, and Dr. William Haseltine for his board service over the last year. At the Meeting, KPMG LLP was reappointed as the Company's independent auditor for the ensuing year and the directors of the Company were authorized to fix the auditor's remuneration. At the Meeting, shareholders passed an advisory resolution approving the compensation of Acasti's named executive officers. In August 2022, the board of directors of Acasti approved amendments to the existing limits of common shares reserved for issuance under the Company's equity incentive plan to set the total number of Common Shares reserved for issuance pursuant to awards granted under the Equity Incentive Plan to an aggregate number that shall not exceed 20% of the issued and outstanding Common Shares as of July 28, 2022, representing 8,898,838 Common Shares, which limit shall include Common Shares issuable pursuant to options issued under the Stock Option Plan. In August, 2022, the Board also approved amendments to the existing limits of Common Shares reserved for issuance under the Company's stock option plan to increase the number of Common Shares that may be issued upon the exercise of all options granted under the plan from 10% of the issued and outstanding Common Shares from time to time to 20% of the issued and outstanding Common Shares as of July 28, 2022, representing 8,898,838 Common Shares, which includes the 4,251,881 Common Shares currently reserved for outstanding options under the Stock Option Plan and which limit shall also include Common Shares issuable pursuant to any awards issued under the Equity Incentive Plan. At the Meeting, disinterested shareholders approved the amendments described above to the Stock Option Plan and the Equity Incentive Plan.

09:08 EDT CareCloud adds remote patient monitoring to suite of digital health solutions - CareCloud announced the launch of its Remote Patient Monitoring, RPM, solution. RPM is the latest addition to the CareCloud Wellness product line, a comprehensive suite of digital health solutions that includes Chronic Care Management, CCM,. RPM gives healthcare providers the ability to monitor aspects of their patients' health outside the clinical setting to proactively improve patient care. CareCloud's new RPM solution utilizes electronic devices, connected through cellular technology, to track and document real-time patient health, such as blood pressure or pulse rate. These devices enable providers with a data-driven understanding of a patients' disease state to proactively support evidence-based clinical decisions and care. "We are helping practices transition into the next generation of healthcare with the addition of Remote Patient Monitoring to our suite of digital health solutions," said CareCloud CEO and President Hadi Chaudhry. "The government's focus on value-based care models and the growth of Internet of Medical Things technology is creating a shift from reactive care to proactive data-enabled care driven by physicians. The addition of RPM to our CareCloud Wellness product line will allow practices to re-frame the patient-provider relationship and enhance their delivery of care."

09:08 EDT Scilex announces pay off of remaining balance of Senior Secured Notes - Scilex Holding Company announced that it pre-emptively paid off and eliminated all of its remaining Notes in an aggregate principal amount of $67.7 million for a cash payment of approximately $39.7 million. Scilex is a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc

09:07 EDT Sintx Technologies announces Phase I grant of $275k awarded by NIH - SINTX Technologies announced a Phase I grant of $275k awarded by the National Institutes of Health, NIH, to develop and test an antimicrobial trauma device. The device will be constructed of a 3D printed continuous carbon fiber, cCF, reinforced polyetherketoneketone, PEKK, plate with silicon nitride embedded into its surface. The Phase I grant represents the third grant awarded to SINTX by the NIH in the past year. SINTX will collaborate with Drexel University, Thomas Jefferson University, and the University of Pennsylvania over the coming twelve months to develop and test this novel infection-resistant trauma plate. The trauma plate will also feature design customization through the 3D printing production method. "Orthopedic trauma procedures can unfortunately have some of the highest infection rates of all surgical specialties. So, the need for antibacterial material characteristics, especially in this area of orthopedic surgery, is tremendous," said Dr. Ryan Bock, Vice President of Research & Development, SINTX Technologies. "We believe that a 3D printed trauma plate which features silicon nitride embedded into the cCF-PEKK material could potentially be a game changer for ortho trauma. We're excited about the possibilities and ready to begin this work under our Phase I NIH grant."

09:05 EDT TrueCar forecasts 1,140,659 total new vehicle sales in Sept., up 13% y/y - TrueCar expects total new vehicle industry sales to reach 1,140,659 units in September 2022, up 13% from a year ago and up 3% from August 2022, when adjusted for the same number of selling days. This month's seasonally adjusted annualized rate for total light vehicle industry sales is an estimated 13.4M, up 9% from September 2021. Excluding fleet sales, TrueCar expects U.S. retail deliveries of new cars and light trucks to be 987,378 units, up 8% from a year ago and up about 3% from August 2022.

09:05 EDT SS&C partners with Coinbase to expand digital asset trading - SS&C Eze has partnered with Coinbase to offer clients access to Coinbase Prime, an institutional platform for digital assets. With the partnership, traders using Eze Investment Suite can manage their crypto trading processes in one place, from pre-trade compliance to custody. Coinbase is trusted by more than 14,500 institutional clients. With the integration, institutional traders on Eze Investment Suite can access a liquidity pool of digital assets, and gain a holistic view of their crypto investments alongside their traditional securities holdings in their portfolios across trading tools.

09:04 EDT LPL Financial announces Bookkeeping Services - LPL Financial announced that the firm's advisors can now access Bookkeeping Services. LPL's newest offering is designed to provide a high level of support by pairing an advisor with an industry-trained bookkeeper who understands their unique business needs. LPL's Bookkeeping Services operates as an extension of the advisor's practice, providing dedicated support to record and categorize financial data and utilize the advisor's commission statements to provide up-to-date reporting. The service begins with onboarding, during which time processes are established to set the stage for long-term success.

09:03 EDT Leslie's publishes annual ESG report - Leslie's released its second annual Environmental, Social, and Governance Report. The report highlights Leslie's priorities and initiatives on environmental stewardship, social commitments, corporate governance, and community service. "For Leslie's, ESG is fundamental to our business. Over the past year, we have made tremendous progress on many of our key initiatives, including expanding our eco-friendly product assortment; furthering a culture of diversity, equity, and inclusion; and developing our first-ever greenhouse gas emissions inventory. These initiatives, among others, are integral to generating long-term value for all our stakeholders," said Michael Egeck, Chief Executive Officer and Director. "We realize there is still more work ahead, but we are confident that as Leslie's grows, so too does our commitment to creating a more positive impact for those around us."

09:02 EDT Kyndryl, Citrix enter workplace collaboration and employee productivity alliance - Kyndryl (KD) announced a global alliance with Citrix (CTXS) to help businesses improve workplace collaboration and employee productivity to address the rapidly changing requirements of today's hybrid workforce on a global scale. By leveraging the longstanding operational and industry expertise of Kyndryl's Digital Workplace Services, powered by Citrix DaaS, both companies will continue to develop modernized, end-to-end IT management services and virtual desktop solutions across hybrid and multi-cloud environments for new and existing customers. Through the alliance, Kyndryl will extend the reach of its framework of flexible workplace modernization services designed and deployed for Citrix's core technologies, including comprehensive desktop and application virtualization managed services that provide secure, remote access to corporate assets from any device or location, while enhancing overall employee satisfaction and end-user experiences.

09:01 EDT SilverSun Technologies trading halted, news pending

08:49 EDT Jaguar Health's Napo announces activation of IND application for NP-300 - Napo Pharmaceuticals announced the activation by the U.S. Food and Drug Administration of the Investigational New Drug application for Napo's NP-300, a novel drug product candidate for the symptomatic relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral and parasitic infections including Vibrio cholerae, the bacterium that causes cholera. Upon completion of the requisite development activities to support the New Drug Application and subsequent approval of NP-300 by the FDA for the symptomatic relief and treatment of diarrhea from cholera, the Company intends to pursue a Tropical Disease Priority Review Voucher under the FDA's financial incentive program to develop NP-300 for this indication. Priority review vouchers are transferable, and in past transactions by other companies have sold for values ranging from $67 million to $350 million, which provides for a potential immediate return on investment upon approval of NP-300 for the cholera-related diarrhea indication.

08:46 EDT Neogen launches new genomic management technology - Neogen has launched the new Encompass platform for bovine genomic results management and visualization. This new data management solution aims to allow Igenity customers to gain greater insight into their data and maximize the benefits of genomic testing. Encompass is part of a larger data environment for producers from iYOTAH Solutions' nTELL platform.

08:46 EDT Jupiter Wellness announces application for dual listing on Upstream - Jupiter Wellness announced that it has begun the application process to dual list its shares on Upstream. The planned dual listing on Upstream is designed to provide Jupiter Wellness the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in NASDAQ-listed Jupiter Wellness.

08:43 EDT Aleafia Health announces results of Annual General Meeting - Aleafia Health announced the results of the vote on the election of directors at its annual meeting of shareholders held on September 27, 2022. All six nominees set out in the management information circular of the Company dated August 19, 2022 were elected to the board of directors of the Company.

08:43 EDT Integra LifeSciences publishes inaugural ESG reprot - Integra LifeSciences issued its inaugural Environmental, Social and Governance, ESG, report. "Our company purpose and values have long guided our global sustainability priorities, and we have a deeply entrenched ESG mindset and culture. Building sustainable organizations not only makes business sense, but it also is the right thing to do," said Jan De Witte, president and chief executive officer, Integra LifeSciences. "Every day, Integra colleagues deliver lifesaving and life-enhancing products and technologies to our customers and fulfill our responsibility to preserve the health of patients and the planet." Highlights of the report include: Identification and ranking of our top 12 ESG priorities; Expansion of board oversight to formally include ESG strategy; An update on our diversity and inclusion efforts; A description of environmental, health, safety, and security policies and governance structure; and calculation of direct greenhouse gas emissions and a commitment to setting concrete reduction targets in the near future.

08:41 EDT Palisade Bio announces oral presentation of Phase 2 data at ACS congress - Palisade Bio announced its abstract was accepted for presentation at the American College of Surgeons, ACS, Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA. Details of the abstract presentation are as follows: Title: LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel Resection. The abstract is now available and can be accessed in the Congress Program Planner. The oral presentation will include new GI functional data sub-cuts from the highly statistically significant Phase 2 clinical study demonstrating LB1148 significantly accelerated the return of post-operative GI function in patients undergoing elective bowel resection. The data sub-cuts are based on laparoscopy and laparotomy with surgical characteristics including, right hemicolectomy, left hemicolectomy, sigmoid and low anterior resection surgery. .

08:41 EDT Saratoga Investment receives approval of third SBIC license - Saratoga Investment announced that it has received notification from the Small Business Administration that the Company's application for a third Small Business Investment Company license has been approved. The new SBIC license will provide up to $175 million in additional long-term capital in the form of SBA-guaranteed debentures, subject to the issuance of a leverage commitment by the SBA. Under current SBIC regulations, for two or more SBICs under common control, the maximum amount of outstanding SBA debentures cannot exceed $350.0 million with at least $175.0 million in combined regulatory capital.

08:39 EDT Rio Tinto starts producing spodumene concentrate in Quebec - Rio Tinto has started producing spodumene concentrate, a mineral used in the production of lithium for batteries, at a demonstration plant in its Rio Tinto Iron and Titanium, or RTIT, Quebec Operations in our metallurgical complex in Sorel-Tracy, Canada. The plant will demonstrate at industrial scale a new spodumene concentration process that provides lithium oxide grades and recoveries well above the industry average. The process was developed by researchers at Rio Tinto's Critical Minerals and Technology Centre and tested on spodumene ore samples from various countries. It offers the environmental benefit of not using chemical products and generating only dry, inert residues.

08:39 EDT T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M - T2 Biosystems announced that the Biomedical Advanced Research and Development Authority, BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, is providing an additional $3.7M in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems. The total potential BARDA funding if all contract options are exercised is $62M, reflecting a reduction in the scope of work under contract option 3. The additional funding will be used to advance the U.S. clinical trials for the T2Resistance Panel and T2Biothreat Panel and file submissions to the U.S. Food and Drug Administration for U.S. regulatory clearance. "We are pleased to advance the U.S. clinical trials for the T2Resistance Panel and T2Biothreat Panel, in collaboration with BARDA, and subsequently file submissions with FDA for U.S. regulatory clearance," stated John Sperzel, Chairman and CEO of T2 Biosystems. "These new products will expand the test menu on our T2Dx Instrument and have the potential to reduce the threat of antimicrobial resistance and protect the nation from biothreat pathogens."

08:38 EDT SuperCom wins new $1.7M contract from existing customer - SuperCom has secured a new $1.7M contract by an existing customer of its e-Government division, with products delivery and services spread over 6 months and expected to start by end of October.

08:36 EDT FSD Pharma receives noncompliance notice from Nasdaq - FSD Pharma announced that it received a written notification from Nasdaq that the company is not in compliance with the minimum bid price requirement set forth in Nasdaq's rules for continued listing on the Nasdaq Capital Market. The notification letter is only a notification of deficiency and not a notice of delisting. As such, the notification letter has no effect on the listing or trading of the company's Class B Subordinate Voting Shares on the Nasdaq.

08:34 EDT Kopin receives $3M production otder - Kopin announced it has received an initial $3M production order for a new weapon sight module. The order calls for deliveries in 2023.

08:33 EDT CACI awarded $174M Navy contract - CACI announced it has been awarded a $174M contract to provide the U.S. Navy Military Sealift Command, or MSC, with mission expertise and innovative solutions for enhancing naval ship machinery, systems, equipment, and structural performance while reducing costs. MSC is responsible for operating and maintaining ships for the Armed Forces and other agencies. Under this task order, CACI will conduct research, analysis, and development to optimize MSC's machinery and structural maintenance program with the goal of reducing ownership costs and technical risks while improving fleet safety, reliability, availability, and readiness.

08:32 EDT Strong Technical Services introduces new digital content delivery service - Strong Technical Services, a wholly-owned subsidiary of Ballantyne Strong, announced that it has initiated a new digital content delivery offering for its cinema partners. The offering enables STS customers to upload and distribute content from one convenient digital feed rather than downloading content files from multiple file-hosting services. "We are committed to helping our cinema partners streamline their operations and this upgraded technology drives efficiencies by providing one seamless content delivery option rather than the retrieval of content from different sources," commented Ray Boegner, President of Strong Entertainment at Ballantyne Strong. "STS has led the way on many innovative technologies in the cinema services industry and we're pleased to diversify our portfolio with the addition of digital content delivery. We are rolling this out to one of our exhibitor partners after successfully piloting at 20 locations and are now offering it to our broader customer base."

08:32 EDT Capstone Green Energy secures order for two C65 microturbine systems - Capstone Green Energy announced that Ractive Engineering, Capstone's distributor in Trinidad and Tobago, secured an order for two C65 ATEX-certified microturbine systems. The microturbines will be fueled by the available on-site unprocessed wellhead gas and provide a reliable power source for the unmanned gas platform located on the eastern coast of Trinidad. The systems will replace obsolete microturbines currently on the platform. The new microturbines are expected to be commissioned in the summer of 2023.

08:31 EDT Ayala Pharmaceuticals to host KOL webinar on desmoid tumors - Ayala Pharmaceuticals announced that it will host a key opinion leader webinar on unmet medical needs and evolving treatment landscape of desmoid tumors on Thursday, October 6, 2022, at 8:00 am ET. The webinar will include presentations by Professors Bernd Kasper, MD, Ph.D., from the Mannheim University Medical Center, and Robin Jones, MD, from The Royal Marsden Hospital and Institute of Cancer Research. Prof. Kasper will discuss the current treatment landscape for desmoid tumors and Prof. Jones will review the positive data from Part A of the ongoing Phase 2/3 RINGSIDE trial of AL102 that were presented at ESMO 2022.

08:29 EDT Sellas Life Sciences presents poster at 2022 SOHO meeting on GFH009 - SELLAS Life Sciences announced data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9, CDK9. In the ongoing Phase 1 clinical trial of GFH009 monotherapy in patients with relapsed/refractory hematologic conditions, including acute myeloid leukemia and lymphoma, GFH009 is administered intravenously as a solution. The bioequivalence study was performed to evaluate the effect of different formulations on GFH009's preclinical pharmacokinetic, PK, profile. Dr. Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS, presented the findings at this year's Meeting of the Society of Hematologic Oncology in a poster titled "Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats." The solution for GFH009 was originally developed with the pH of 4.5. Human blood has a physiological pH of around 7.35 to 7.45. The closer a drug is to this physiological state, the less acidic and irritating it is for patients. In a four-week rat study, GFH009 was tested at 2.0 mg/kg, 4.0 mg/kg and 8.0 mg/kg. At 4.0 mg/kg, drug exposure approached efficacy, which formed the rationale for the dose selection for the presented PK study. Rats were randomly assigned to group one or group two and matched by sex and body weight. Each rat received a single dose of GFH009 at pH 4.5 or pH 6.0 intravenously in the tail vein at a volume of 5.0 mL/kg. The PK profiles of both GFH009 formulations were found to be comparable, supporting the application of the pH 6.0 formulation in the ongoing Phase 1 clinical trial.

08:27 EDT Newtek selects Apiture's digital banking platform to power Newtek bank - Newtek Business Services announced it has selected the Apiture Digital Banking Platform to support the digital capabilities of Newtek Bank, pending regulatory approvals and the close of the acquisition of the National Bank of New York City, NBNYC. Newtek plans to leverage Apiture's Business Banking and Account Opening solutions in combination with Newtek's existing suite of business and finance solutions and the Newtek Advantage to deliver a comprehensive suite of financial and business solutions and services to independent business owners. Barry Sloane, Chairman, President and Chief Executive Officer said, "We believe Newtek Bank will become a true bank of the future, offering all our business customers the banking and business services they need in a branchless environment. By partnering with Apiture, we will be able to deliver the comprehensive digital banking capabilities our customers will require along with the outstanding customer experience they expect online today." Sloane continued, "In addition to the Apiture partnership, the Newtek Advantage will underscore the Company's mantra that Newtek is the 'One Solution For All Your Business Needs.' The Newtek Advantage needs to be understood as part of the Newtek ecosystem that deploys more than 20 years of experience developing an all-encompassing 'process, people and a technological system' that improves the lives of our business clients. The repositioning of Newtek as a bank holding company, owning a nationally chartered regulated bank, will give us the central point that our business clients come to daily, weekly and monthly to manage their business... We chose Apiture as our initial digital platform provider and integrator into Newtek Bank due to its commitment to deliver on-time digital account opening, and rebranding our technology through NBNYC's existing core operating system without having to go through a core conversion with when we open."

08:26 EDT Berkshire Hathaway increases Occidental Petroleum stake by $352.5M - In a regulatory filing, Occidental Petroleum disclosed that its major shareholder Berkshire Hathaway bought 5.99M shares of common stock in a total transaction size of $352.5M on September 26th.

08:24 EDT Dorman Products names Dickerson as VP, Investor Relations & Risk Management - Dorman Products announced the addition of Michael Dickerson as Vice President, VP, Investor Relations & Risk Management effective September 26, 2022. Mike served most recently as Vice President, Investor Relations and Corporate Communications for The Aaron's Company, Inc. and its predecessor Aaron's.

08:21 EDT Femasys announces commercial availability of FemCerv - Femasys announced the commercial availability of FemCerv, the first endocervical tissue sampler designed to improve tissue quality and quantity that is expected to be an improvement over the existing standard of care. The Company also announced the hiring of Michael Meier as Vice President of Sales and Marketing. "In line with developing solutions to improve the continuum of healthcare options for women, we are pleased to announce the commercial availability of FemCerv," said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. "If a woman's pap smear is abnormal, she generally needs to undergo a colposcopy, which includes endocervical curettage or taking a tissue sample from the very sensitive cervical canal. The tools available to collect this tissue are limited and can cause pain and extreme discomfort, often resulting in an inadequate or contaminated sample. FemCerv can be used in place of these antiquated products to capture and protect a comprehensive 360-degree tissue sample in a relatively pain free office visit. Now women and their healthcare providers can feel confident to rely on the accuracy of their results, potentially sparing women from unnecessary repeat examinations or more invasive procedures." Meier brings over 20 years of commercial experience to the Femasys team. Meier was previously the head of business development and payor relations at Gravity Diagnostics.

08:19 EDT Genetic Technologies announces recent publication on GeneType Risk Test - Genetic Technologies announces the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician. Publication highlights: Publication highlights the utility of GeneType Risk Prediction Tools in Precision Medicine; Paper outlines the utility accepted for publication in Journal of Precision Medicine; Publication highlights the importance of incorporating risk stratification in preventative care; GeneType Risk Assessment Test outperforms traditional risk assessments for breast cancer improving the potential for an overall improvement in preventative care; GeneType Risk Assessment Test for breast cancer shows a 9-fold improvement in identifying at-risk women when compared with traditional risk assessment tests. The paper, titled "Integrating Personalised Medicine into Preventative Care through Risk Stratification", outlines how GTG's geneType suite of risk assessment tools integrating common genomic markers of risk with traditional epidemiological risk factors, result in a net improvement in stratification over traditional risk assessments. In a side-by-side comparison of clinical risk assessment models taken from data from the Nurses' Health Study the geneType Risk Assessment Test for breast cancer showed a 9-fold improvement in identifying at-risk women when compared with traditional gold-standard, 22.4% of women compared to 2.5% over the actionable threshold respectively. The publication includes three examples of discussions with patients and their clinicians where a clinician has the opportunity to use a risk score, such as geneType, to communicate a patient's personal risk of developing disease. The simple risk report enables the clinician to communicate risk in a standard format, within the confines of clinically actionable thresholds ultimately resulting in improved patient outcomes.

08:18 EDT SKYX Platforms secures 10-year roof right lease, corporate headquarters in Miami - SKYX Platforms announced that it secured a 10-year roof right lease for signage on one of the tallest buildings in downtown Miami, across the street from the Miami Heat FTX Arena and Biscayne Bay. As part of the lease, SKYX has also secured a high ceiling office space with 360-degree views and expects to open its U.S. and international sales offices, as well as its corporate headquarters, in the new location in 2023. As part of the agreement, the company can start paying rent in January 2024. In addition, the Landlord will provide the company with an improvement allowance of up to $2.25M, which may be used for the construction of the premises, including the reasonable cost of design, space planning, consultants, and construction drawings. The company intends to use part of the office space and to sublease the remainder to minimize expenses.

08:17 EDT Ocuphire Pharma expands medical advisory board with seven new KOLs - Ocuphire Pharma announced that it has appointed seven new Key Opinion Leaders, KOLs, across retina, cornea/refractive, and medical optometry to its Medical Advisory Board. In addition, Ronil Patel, M.S. has been promoted to Vice President, Business Development and Market Strategy. The new members of the Medical Advisory Board are: Vitreoretinal Surgeons: Anat Loewenstein, M.D. is Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Center and Professor of Ophthalmology and Vice Dean at Tel Aviv University. Caroline Baumal, M.D. is a Professor of Ophthalmology at Tufts Medical Center and co-director of the retina service and medical retina fellowship at New England Eye Center in Boston, MA. Cornea and Refractive Surgeons: Zaina Al-Mohtaseb, M.D. is a cornea, cataract, and refractive surgeon at Whitsett Vision Group in Texas. Inder Paul Singh, M.D. is President of The Eye Centers of Racine and Kenosha in Wisconsin. Medical Optometrists: Leslie O'Dell, O.D. is the medical director of Medical Optometry America in Pennsylvania. Selina McGee, O.D. is Founder, Chief Optometrist, Executive and Visionary at BeSpoke Vision in Oklahoma and Adjunct Assistant Professor at the Northeastern State University College of Optometry. Justin Schweitzer, O.D. is the optometric externship director at Vance Thompson Vision in Sioux Falls, South Dakota. In addition to the appointment of new MAB members, Ocuphire announced the promotion of Ronil Patel, M.S, to Vice President, Business Development and Market Strategy.

08:14 EDT Roku to enable four-screen ad campaign measurement in Nielsen platforms - Roku (ROKU) will enable four-screen measurement for the first time across traditional TV, connected TV, desktop, and mobile in Nielsen (NLSN) Total Ad Ratings. Now, marketers running ads with Roku can deduplicate campaign reach and frequency across all four screens in the home. Nielsen Four-Screen Ad Deduplication will initially be available in Nielsen Total Ad Ratings and will underpin audience deduplication in Nielsen ONE, the company's forthcoming cross-media measurement platform, upon release in December. This measurement is available on the Roku platform, inclusive of any Roku media running through OneView and video inventory on Roku Ad Framework certified channels. OneView, Roku's ad platform built for TV streaming, is directly integrated with Nielsen's measurement solution. Nielsen Four-Screen Ad Deduplication aims to deduplicate audiences across devices, services and platforms in Nielsen ONE, to provide a consistent, comparable, and deduplicated view into the channels and platforms audiences consume, across screens.

08:13 EDT Harsco signs contract with Saudi Railway Company - Harsco announced that its rail division has signed a nearly $31M contract with Saudi Railway Company, SAR, to provide it with a 60-stone rail grinder. Additionally, to support the immediate needs of the customer, Harsco Rail will provide two years of grinding services starting in 2022. "Our continued relationship with the Saudi Arabia and Middle Eastern markets is a significant milestone for us," said Claus Heuschmid, Harsco Rail's Chief Operating Officer. "This contract demonstrates Saudi Railway Company's confidence in Harsco Rail as a valued supplier that delivers innovative and sustainable advanced products. We look forward to a long relationship with SAR, and we are very appreciative of the trust they have placed in us."

08:12 EDT Carvana down 7% at $24.95 following Q2 earnings miss by CarMax

08:11 EDT Northern Lights Acquisition completes acquisition of SHF, changes company name - Northern Lights Acquisition (NLIT) has completed its previously announced acquisition of SHF, d/b/a Safe Harbor Financial, offering compliance services to financial institutions that serve the regulated cannabis industry. With the transaction now complete, the company has changed its name to SHF Holdings (SHFS). Its Class A Common Stock and warrants will continue to be listed for trading on the Nasdaq Capital Market. The company also closed on September 28 a PIPE in the amount of $20.45M of convertible preferred stock and warrants. To offset the reduced PIPE amount, Partner Colorado Credit Union, Safe Harbor's indirect parent, agreed to provide for the deferral of approximately $57M of the $70M due to the seller at the closing of the business combination. The increase in the Deferred Cash Consideration will provide the company with additional cash to support its post-closing activities.

08:09 EDT Lordstown Motors starts commercial production of Endurance pickup truck - Lordstown Motors announced that it has started commercial production of its Endurance full-size pickup truck, and provided a business update. Start of production of commercially saleable Endurance vehicles at the Foxconn EV Ohio plant; Production volume will ramp slowly as a result of supply chain constraints; engineering readiness, quality, and part availability will continue to govern the speed of launch; FMVSS confirmation crash testing successfully completed; Endurance has been named as one of only three semi-finalists in the North American Truck of the Year competition; Confirming Q4 start-of-sales, subject to full homologation testing and required certification; Expect to end the quarter with cash and cash equivalents of approximately $195 million; Continue to explore capital raising alternatives, including in connection with initial Foxconn JV program and strategic partnership discussions. "We anticipate ending the third quarter with approximately $195 million in cash and cash equivalents, including $27.1 million of proceeds from equity issuances during the third quarter of 2022. We now anticipate ending 2022 with approximately $110 million in cash and cash equivalents, excluding both any additional capital raises and funding of any contingent liabilities. Our cash outlook is better than our previous outlook by approximately $75 million and we continue to explore opportunities for capital raising alternatives, including in connection with the initial Foxconn JV program and strategic partnerships."

08:09 EDT Alzamend Neuro submits ALZN002 IND application to FDA - Alzamend Neuro announced that it submitted an investigational new drug, or IND, application to the FDA for its immunotherapy product candidate ALZN002. The product candidate is designed to treat mild to moderate dementia of the Alzheimer's type. ALZN002 is a proprietary "active" immunotherapy product, which means it is produced by each patient's immune system. It consists of autologous dendritic cells, or DCs, that are activated white blood cells taken from each individual patient so that they can be engineered outside of the body to attack Alzheimer's-related amyloid-beta proteins. These DCs are pulsed with a novel amyloid-beta peptide, or E22W, designed to bolster the ability of the patient's immune system to combat Alzheimer's; the goal being to foster tolerance to treatment for safety purposes while stimulating the immune system to reduce the brain's beta-amyloid protein burden, resulting in reduced Alzheimer's signs and symptoms. Compared to passive immunization treatment approaches that use foreign blood products, active immunization with ALZN002 is anticipated to offer a more robust and long-lasting effect on the clearance of amyloid. This could provide a safer approach due to its reliance on autologous immune components, using each individual patient's own white blood cells rather than foreign cells and/or blood products.

08:07 EDT VBI Vaccines initiates enrollment in VBI-2901 trial - VBI Vaccines announced the initiation of enrollment in the Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle coronavirus vaccine candidate expressing the full-length spike proteins from the SARS-CoV-1, SARS-CoV-2, and MERS-CoV viruses.

08:06 EDT Endeavour Mining appoints Sakihla Mirza to board of directors - Endeavour Mining is pleased to announce the appointment of Sakhila Mirza to the Board as an Independent Non-Executive Director, effective today. Sakhila Mirza is currently General Counsel and an Executive Director of the Board of the London Bullion Market Association, leading their sustainability, responsible sourcing and ESG agenda. She is responsible for the LBMA's legal, governance and compliance functions, liaising closely with precious metals industry participants on establishing market standards and policies.

08:06 EDT Biohaven Pharmaceutical provides update on verdiperstat Phase 2/3 trial in ALS - Biohaven Pharmaceutical announced results from a focused analysis of treatment with verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis - ALS -. The HEALEY ALS Platform Trial, the first-ever platform trial in ALS, is designed as an adaptive trial to evaluate multiple investigational treatments simultaneously. Verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy outcome, disease progression measured by the ALS Functional Rating Scale-Revised and survival, nor the key secondary efficacy measures during the 24-week study period. Initial analysis of safety data was consistent with the overall profile of verdiperstat from prior clinical trial experience. Additional analyses are ongoing, and complete study results will be presented at an upcoming scientific meeting.

08:05 EDT BIO-key demonstrates cybersecurity solutions at ScanSource conference - BIO-key International announced it will demonstrate its solutions and meet with partner prospects at 2022 ScanSource Channel Connect in Nashville, TN, October 2-5. ScanSource Channel Connect combines for the first time the ScanSource Partner Conference and Intelisys Channel Connect to create an even greater opportunity for partners and suppliers to gain knowledge, strengthen relationships, and create new partnerships.

08:04 EDT Enbridge acquires Tri Global Energy for $270M in cash and assumed debt - Enbridge announced it has acquired Tri Global Energy, a US renewable project developer, for $270M in cash and assumed debt. Additionally, up to approximately $50M in payments could be made contingent on successful execution of TGE's project portfolio. TGE is currently the third largest onshore wind developer in the US, with a development portfolio of wind and solar projects representing more than 7 GW of renewable generation capacity. TGE's large development portfolio is well-positioned to capitalize on this growth, including 3.9 GW of renewable generation projects TGE previously sold to operators, which will generate development fees and accretion to distributable cashflow per share in the first year following the acquisition of TGE. In addition, 3 GW of late-stage development of wholly owned projects are expected to be placed into service between 2024 and 2028, providing a visible ramp up in cash flows along with a large slate of further projects in earlier stage development beyond that period. The TGE team has successfully developed and monetized over 6 GW of utility scale renewable projects since its inception in 2009. TGE's development team will remain in place following closing of the transaction, ensuring continuity of ongoing development activities.

08:03 EDT General Motors and OneD Battery Sciences partner in EV battery R&D - General Motors and OneD Battery Sciences executed a joint research development agreement focused on the potential use of OneD's silicon nanotechnology in GM's Ultium battery cells to drive increases in energy density for longer range and reduced cost. GM Ventures and Volta Energy Technologies also participated in OneD's Series C funding round, which the company recently closed at $25M. The focus of the collaboration is OneD's SINANODE platform, which adds more silicon onto the anode battery cells by fusing silicon nanowires into EV-grade graphite. Silicon can store 10 times more energy than graphite. GM is rapidly scaling its Ultium EV Platform to reach 1 million units of annual EV manufacturing capacity in North America by 2025. Earlier this year, GM's first Ultium Cells joint venture battery plant began production in Ohio, with two additional U.S. plants under construction and a fourth also planned.

08:00 EDT Loop Media director buys $2.3M in common stock - In a regulatory filing, Loop Media disclosed that its director Bruce Cassidy bought 460K shares of common stock on September 26th in a total transaction size of $2.3M.

07:42 EDT DT Midstream increases ownership in Millennium Pipeline - DT Midstream announced that it has entered into an agreement to acquire an additional 26.25% ownership interest in Millennium Pipeline for approximately $552M in cash. The transaction will be financed with cash on hand and available capacity under the company's revolving credit facility. Under the terms of the agreement, DTM will acquire National Grid's full ownership interests in Millennium Pipeline, which, upon closing, will bring DT Midstream's total ownership in Millennium Pipeline to 52.50%. "Increasing our ownership in a premium integrated asset like Millennium Pipeline directly aligns with our strategic investment thesis and accelerates our growth plan," said David Slater, President and CEO of DT Midstream. "This transaction also increases the revenue contribution from our pipeline segment, underpinned by take-or-pay contracts with high credit quality customers," added Slater.

07:41 EDT NexGel appoints Nelson, Chesen to scientific advisory board - NEXGEL announced that the Company has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board. Dr. Nelson serves as Co-Director of the pediatric ophthalmology department and Director of the Strabismus Center at Wills Eye Hospital. He is an associate professor of ophthalmology and pediatrics at Thomas Jefferson University's Sidney Kimmel Medical College and staff member at Thomas Jefferson University Hospital, Lankenau Medical Center and Children's Hospital of Philadelphia. In addition to Dr. Nelson, Dr. Chesen is a board-certified ophthalmologist who has been in private practice at Chesen Laser Eye Center for 33 years, with extensive experience in cataract and LASIK procedures. He is also board-certified in internal medicine.

07:40 EDT SL Green Realty inks lease with Franklin Templeton at One Madison Avenue - SL Green Realty announced that investment management firm Franklin Templeton has signed a 15-year, 347,474 square foot lease at One Madison Avenue. The company will occupy the entire 11th through 22nd floors in the tower portion of the building. This lease follows the recently announced 328,000 square foot lease with International Business Machines Corporation and the 56,000 square foot lease with Chelsea Piers Fitness. The neighborhood defining development, which is on schedule for completion in November 2023, is now 55% leased.

07:40 EDT Bed Bath & Beyond on track for 14 new buybuy Baby store openings in FY22 - Comments taken from Q2 earnings conference call presentation slides.

07:37 EDT Worthington CEO says businesses 'holding up well' despite market volatility - "Most of our businesses are holding up well despite increased market volatility and a murky economic outlook. Our teams are ready to respond to market demands, up or down, as changes occur," CEO Andy Rose said. "In addition, we are very excited to announce our plan to separate our Steel Processing business to create two market leading companies with a proud shared history and values. The separation represents a major milestone for our company, and I am confident that this move will position both businesses to capitalize on focused growth strategies to better serve their customers and unlock significant shareholder value."

07:36 EDT Lilium announces a partnership with GlobeAir - Lilium has announced a partnership with GlobeAir. Under the agreement, GlobeAir intends to purchase 12 Lilium Jets to provide premium and business eVTOL flights to its customer base in the French Riviera and Italy. The sustainable Lilium Jet will complement GlobeAir's current offerings in the French Riviera and Italy with a first and last mile service. Enabling considerable time savings for customers, the partnership will exemplify the all-in-one travel experience GlobeAir specializes in. Sebastien Borel, SVP Commercial, Lilium, said: "We are thrilled to be partnering with one of the leading European providers in on-demand air mobility, GlobeAir. The French Riviera and Italy are key markets, and we are confident that our shared commitment to innovation and partnership will result in a premium customer experience."

07:33 EDT Bed Bath & Beyond says 'we are seeing signs of continued progress' - Sue Gove, Director & Interim CEO of Bed Bath & Beyond said, "Our results for the second quarter came in as previously expected and announced. While our sales and profit results do not yet reflect the strategic and financial actions we have initiated to change our performance, they do demonstrate sequential progress in several key areas. In the first quarter, we experienced a significant dislocation between sales and inventory that we began to address immediately during the second quarter. Aggressive inventory optimization actions, including accelerated markdowns and strategic promotions, led to double digit improvement in this gap. Working with our supplier partners has also been an important focus area and our payables are considerably healthier than in the prior quarter as evident on our balance sheet. Gove continued, "Although still very early, we are seeing signs of continued progress as merchandising and inventory changes begin. For example, we have seen positive sales trends where in-stock positions and visual merchandising have improved. Our Welcome Rewards loyalty program also continues to gain momentum with membership expanding by more than 1.3 million since the end of August, for a total of 6.4 million members since launching this summer. Enrolled members represent more frequent purchases and higher transaction values across all three banners. Our buybuy BABY business continues to hold market share relative to other mass market retailers in today's highly competitive environment. We are enhancing our capabilities while leveraging Welcome Rewards, such as the relaunch of our Baby registry business later this fiscal year, increasing the effectiveness of marketing investments, and realizing the strategic shift of our merchandise assortment which had minimal impact in this quarter, all targeted to drive customers and top-line growth. We have worked quickly to deploy strategic and financial changes swiftly to increase cash through business growth and lowering our cost structure by approximately $250 million in the second half of fiscal 2022, or an expected $500 million on an annualized basis. We are confident that our current liquidity will enable the necessary changes we are implementing. I want to thank our teams for their proven dedication and resilience during this extraordinary and important time for our organization. We are more focused than ever on demonstrating improvement in the coming quarters. Regaining market share and enhancing liquidity are our top priorities."

07:33 EDT Worthington plans to separate Steel Processing business into public company - Worthington Industries announced that its Board of Directors unanimously approved a plan to pursue a separation of the Company's Steel Processing business into a new public company. Worthington Industries plans to effect the separation via a distribution of stock of the Steel Processing business, which is expected to be tax-free to shareholders for U.S. federal income tax purposes. The Company expects to complete the separation by early 2024. The planned separation will result in two independent, publicly traded companies, each poised to capitalize on differentiated growth and value creation strategies. The post-separation Worthington is positioned with premier brands in fast-growing, attractive end markets in Consumer Products, Building Products and Sustainable Energy Solutions. The post-separation Steel Processing business will be a best-in-class, value-added steel processor with a unique capability set, sophisticated supply chain and pricing solutions and expanded product offerings in electrical steel laminations and laser welding solutions. The McConnell family is expected to continue as a meaningful, long-term shareholder of both companies. New Worthington will be a market-leading company with premier brands in attractive end markets in Consumer Products, Building Products and Sustainable Energy Solutions. As a more focused company, New Worthington will be well-positioned to capitalize on key trends in sustainability, technology, remodeling and construction and outdoor living. New Worthington will continue to pursue a growth strategy focused on leveraging its robust new product pipeline of sustainable, tech-enabled solutions to disrupt mature markets. New Worthington will continue to leverage the Worthington Business System, which powers a winning culture and higher growth and profitability through Transformation, Innovation and Acquisitions. The new company's high margins and asset-light focus is expected to enable strong free cash flow generation and returns for shareholders. Further, New Worthington's value will no longer be highly correlated to the price of steel, providing the opportunity for premium sector multiples. For fiscal year 2022, Worthington's Consumer Products, Building Products and Sustainable Energy Solutions businesses delivered $1.3 billion in sales and adjusted EBITDA of $340 million, an increase of 47% compared to the $232 million of adjusted EBITDA generated during fiscal year 2021. Post-separation, New Worthington intends to continue its balanced approach to capital allocation and maintain a strong balance sheet and a dividend policy that is consistent with its historic practice. Following the completion of the separation, New Worthington will continue to be led by Andy Rose and will maintain its headquarters in Columbus, Ohio.Following the separation, Worthington Steel will be a best-in-class, value-added steel processor and producer of electrical steel laminations and automotive lightweighting solutions, positioned to capitalize on expanding opportunities in electrification, sustainability and infrastructure spending. Worthington Steel will have a unique capability set and sophisticated supply chain and pricing solutions to serve its blue chip customers, grow market share and increase margins. The Company will continue leveraging the Worthington Business System to power a winning culture, higher growth and profitability through Transformation, Innovation and Acquisitions. For the fiscal year 2022, Worthington's Steel Processing business generated $3.9 billion in sales and $259 million of adjusted EBITDA. Worthington Steel intends to continue its balanced approach to capital allocation and maintain a strong balance sheet and a dividend policy that is consistent with Worthington Industries' historic practice. Geoff Gilmore, currently Chief Operating Officer of Worthington, will serve as Chief Executive Officer of Worthington Steel, which will be headquartered in Columbus, Ohio. Completion of the separation is subject to, among other things, general market conditions, finalization of the capital structure of the two companies, completion of steps necessary to qualify the separation as a tax-free transaction, receipt of regulatory approvals and final approval by the Company's Board of Directors. Following the separation, New Worthington expects to continue to be publicly traded on the New York Stock Exchange and expects Worthington Steel to also be publicly listed. Specific details about Board members, executive leadership and management teams will be made available in due course. The separation is expected to be completed by early 2024, but there can be no assurance regarding the ultimate timing of the separation or that the separation will ultimately occur.

07:32 EDT Bed Bath & Beyond maintains FY22 outlook - As previously announced with the company's Business and Strategic Update on August 31, 2022, the company is maintaining the following outlook parameters for fiscal 2022: Comparable Sales decline in the 20% range driven by improvements in the second half of fiscal 2022 versus the first half of fiscal 2022; Adjusted2 SG&A expense approximately $250 million below last year, reflecting cost optimization actions occurring in the second half of fiscal 2022; Capital Expenditures of approximately $250 million versus the company's original plans of approximately $400 million previously planned for fiscal 2022. Based on these guidance parameters, as well as ongoing working capital management and the timing of SG&A savings, planned reductions in capital expenditures and future store closures, the company anticipates breakeven operating cash flow by the end of fiscal 2022.

07:30 EDT IntercontinentalExchange announces FCA requirement of sterling LIBOR settings - Intercontinental Exchange announced that the U.K. Financial Conduct Authority, or FCA, has decided to require ICE Benchmark Administration, or IBA, to continue to publish one- and six-Month "synthetic" sterling LIBOR settings until March 31, 2023. The FCA has announced that, following the results of a consultation, it has no intention to use its powers to compel IBA to continue to publish the one- and six-Month "synthetic" sterling LIBOR settings beyond this date, and that therefore these settings will permanently cease immediately after final publication on March 31, 2023. The FCA also consulted on when it could cease to compel IBA to publish three-month "synthetic" sterling LIBOR and noted there was support for requiring the continuation of three-month "synthetic" sterling LIBOR for a limited period beyond the end of March 2023. The FCA is considering the appropriate date for such cessation in light of the feedback received, and will provide further information when it publishes its summary of feedback on that question.

07:20 EDT Weyerhaeuser sees Q3 Timberlands earnings comparable to 3Q21 - The prior outlook was lower than Q2, but moderately higher than 3Q21. Sees Q3 Real Estate, Energy & Natural Resources earnings slightly lower than 3Q21, unchanged from its prior view. Sees Q3 Wood Products earnings approximately $40M lower than Q2 vs. prior view of comparable to Q2.

07:17 EDT Weyerhaeuser targeting $175M-$200M of opex margin improvements 2022-2025 - Comments taken from investor presentation slides.

07:15 EDT Ero Copper announces discovery of nickel sulphide system in Curaca Valley - Ero Copper announces the discovery of a regional nickel sulphide system within the Curaca Valley over an initial strike length of five kilometers. The system remains open in all directions and is highlighted by multiple surface expressions of nickel mineralization. Commenting on the discovery, David Strang, Chief Executive Officer, said "This is a significant and pivotal moment for the Company and, more broadly, for the region... As a Company, we have been working to better understand the potential for nickel occurrences since first observed within the Vermelhos Mine in 2018. With newly compiled datasets, dedicated resources focused exclusively on understanding and finding nickel and a complete re-look of several historic datasets this past year, our efforts and persistence have paid off. We believe today's results confirm the Curaca Valley's potential to be a globally significant magmatic sulphide district for both copper and nickel."

07:13 EDT Enthusiast Gaming sells select legacy assets for C$6.8M - Enthusiast Gaming Holdings announced the sale of certain video game editorial websites for a purchase price of approximately C$6.8M, representing a multiple of approximately 4.5x associated revenue. Between the sale and the Company's expanded credit facility announced on September 19, 2022, the Company has bolstered its balance sheet with over C$16.8M of non-dilutive capital in recent weeks while reducing operating costs in the business. Among the Website Assets included as part of the sale are Destructoid.com, Siliconera.com, Upcomer.com, PCInvasion.com, Operationsports.com and EscapistMagazine.com, together with their respective social media handles and the Company's rights to certain legacy domains and related content such as NintendoEnthusiast.com.

07:11 EDT PharmaTher reports $12M in cash, investment on balance sheet - Fabio Chianelli, CEO of PharmaTher, said, "We had achieved important clinical and business milestones that will pave the way for PharmaTher to potentially become a commercial-stage company in 2023. With a little over $12 million in cash and investment on our balance sheet, we are in a strong position to advance our ketamine-based clinical development and commercial programs to treat mental health, neurological and pain disorders. To support our commercial objectives, we aim to file abbreviated new drug applications with the FDA for our ketamine injectable products for anesthesia and procedural sedation. We expect to obtain FDA approvals by 2H-2023. Our clinical development objectives for the next twelve months include obtaining FDA agreement to conduct a potential Phase 3 clinical trial evaluating ketamine for Parkinson's disease, present results from the Phase 2 clinical trial evaluating ketamine for Amyotrophic Lateral Sclerosis, present clinical study results in depression and pain with our ketamine microneedle patch and ketamine wearable pump device, and partner with pharmaceutical companies for our ketamine products, drug delivery systems and clinical programs. Finally, I like to thank the PharmaTher team, our Board of Directors and our shareholders for supporting our objective in unlocking the therapeutic potential of ketamine for unmet medical needs."

07:11 EDT Gamida Cell announces long-term data from omidubicel study - Gamida Cell announced the presentation of new long term follow-up data and health-related quality of life scores of patients treated with omidubicel at the Tenth Annual Meeting of the Society of Hematologic Oncology, or SOHO, being held in Houston, Texas. The long-term, durable clinical benefit of omidubicel was observed at three years across a patient population that typically has a poor prognosis. A study highlighted long-term follow-up of 105 patients transplanted with omidubicel between 2006-2020. The data demonstrated an overall survival and disease-free survival of 63% and 56% at three years, respectively, as well as durable long-term hematopoiesis and immune competence. Overall well-being health-related quality of life scores for patients treated with omidubicel demonstrated clinical benefit compared to standard of care. A study featured an analysis of 108 patients that completed validated health-related quality of life surveys on screening and days 42, 100, 180, and 365 post-transplant. Measures of physical and functional well-being and other HRQL scores were more favorable with omidubicel. These data suggest clinically meaningful and sustained improvements in physical, functional, and overall well-being compared to umbilical cord blood transplantation.

07:08 EDT Silence reports preliminary results from single dose part of GEMINI II trial - Silence Therapeutics announced preliminary results from the single dose component of the GEMINI II phase 1 study of SLN124, a siRNA targeting the TMPRSS6 gene, in 24 adults with non-transfusion dependent thalassemia. The primary objective of the single dose arm was to evaluate the safety and tolerability of SLN124 subcutaneous dosing in alpha/beta-thalassemia patients. Following a single dose, there were no serious adverse events, severe treatment emergent adverse events, or TEAEs, that were SLN124 related or TEAEs leading to withdrawal. No dose limiting toxicities or drug related liver injury were observed. Pharmacokinetic parameters and pharmacodynamic biomarkers of iron metabolism are being evaluated in the ongoing multiple dose arm of the study which is anticipated to readout next year. This includes effects on hepcidin, serum iron, transferrin saturation and hemoglobin.

07:08 EDT Skylight Health to participate in Medicaid value-based care model in Colorado - Skylight Health Group provides an update on the addendum to its current Medicaid contract into Colorado's new Alternative Payment Model 2 for effective start date January 2023Skylight currently has over 20K Medicaid members in Colorado. The Company will begin participating in the new care model in January 2023 and is expected to have over 20K attributed Medicaid members. VBC ties reimbursements to the quality of care delivered, rewarding healthcare providers for both efficiency and effectiveness as opposed to the fee-for-service model, which relies on historical bill charges or annual fee schedules. In addition, VBC models focusing on members' long-term health outcomes deliver higher profitability to providers. The new APM 2 allows primary care providers to shift from fee-for-service to a capitated value-based-care per member per month reimbursement model as well as shared savings in improved patient quality thresholds. This addendum is expected to allow Skylight to benefit from increased funding for its Medicaid members to improve on quality and care management. This greatly accelerates Skylight's shift to value-based-care, leveraging analytics and decision support tools of the Company's joint venture with Centene Corp and CHS Medical.

07:05 EDT XPO Logistics announces Ratti as Chief Human Resources Officer for RXO spin-off - XPO Logistics announced that Heidi Ratti will become chief human resources officer of RXO, the planned spin-off of XPO's tech-enabled brokered transportation platform. Ratti is currently senior vice president, human resources for XPO's North American less-than-truckload business, and will move to RXO's C-suite when the separation is complete. She will report to Drew Wilkerson, who, as previously announced, will be chief executive officer of RXO, and currently serves as president, transportation - North America.

07:04 EDT Tiziana Life Sciences CMO purchases 25,000 common shares - Tiziana Life Sciences announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 25,000 common shares at $0.75 per share, bringing his total holding to 200,000 common shares.

07:02 EDT AN2 Therapeutics awarded $17.8M contract from NIH - AN2 Therapeutics announced the award of a contract valued up to $17.8M from the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH, to advance the development of epetraborole for acute systemic melioidosis. The base period contract is $4.3M with additional options that, if exercised, will total $17.8M to support preclinical, Phase 1 studies and other activities to enable advancement of epetraborole into a pivotal Phase 2/3 clinical trial for acute systemic melioidosis. AN2 Therapeutics is currently developing epetraborole in an ongoing pivotal Phase 2/3 trial for treatment refractory Mycobacterium avium complex lung disease, the most common form of nontuberculous mycobacterial lung disease. "Melioidosis, a disease caused by the bacteria Burkholderia pseudomallei, is predominately a disease of tropical climates, especially in South Asia and northern Australia where it is widespread. However, B. pseudomallei was recently found in the environment along the Gulf Coast in the United States," said Eric Easom, Co-Founder, President and Chief Executive Officer. "Epetraborole has shown significant promise in non-clinical models of infection for melioidosis and could have the potential to reduce mortality in patients suffering from the disease. In addition to addressing an urgent unmet global health need, this work will aid in addressing a high priority biothreat pathogen and will allow us to capture synergies with our ongoing development of epetraborole for NTM. We are pleased to partner with the NIH on this meaningful global health work that is core to our corporate mission and values."

07:01 EDT Palantir granted contract expansion with U.S. Army Research Laboratory - Palantir announced the U.S. Army Research Laboratory will extend its work with the company to support all branches of the Armed Services, Joint Staff, and Special Forces as they test, utilize, and scale artificial intelligence and machine learning capabilities across the Department of Defense . The contract is worth up to $229M over one year. Palantir's software will continue to support warfighters, the data science community, and commercial AI companies across all facets of AI/ML research and development within the DoD. This extension will enable the Department to scale these critical capabilities to additional mission areas as well as emerging priorities.

06:55 EDT CarMax drops 8% to $79.00 after Q2 results miss estimates

06:46 EDT Wex launches Flume, an FDIC-insured digital wallet - Wex announced the public launch of Flume, an FDIC-insured digital wallet uniquely designed to bridge the digital divide for millions of small-and-medium-sized businesses in the U.S. Flume is provided by WEX Payments, a state-licensed money transmitter, in conjunction with a partner commercial bank. Nationwide, more than 40% of B2B payments are paid by check, and two-thirds of businesses process payments by hand, leaving them vulnerable to fraud, human error, and costly delays. And while digital payment options exist, most software is designed for large companies, creating an insurmountable barrier for small businesses. Flume was built to address this growing need by offering a one-stop shop where small businesses can simply manage their business from one login.

06:32 EDT SpringsWorks Therapeutics doses first patient in Phase 2 trial of nirogacestat - SpringWorks Therapeutics announced that the first patient has been dosed in a Phase 2 trial evaluating nirogacestat, SpringWorks' investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors. Ovarian granulosa cell tumors account for approximately 5% of all ovarian cancers and are the most common subtype of ovarian sex cord tumors, representing 70% of all cases. The Phase 2 trial is a single-arm study evaluating the efficacy, tolerability, safety, and pharmacokinetics of nirogacestat in patients with recurrent ovarian granulosa cell tumors. The study will enroll approximately 40 patients who will receive 150mg of nirogacestat twice daily. Eligible patients will have recurrent ovarian granulosa cell tumors and will have received one or more prior lines of systemic therapy. The primary endpoint of the trial is objective response rate. Secondary endpoints include progression-free survival, overall survival, duration of response, safety and tolerability, and quality of life assessments.

06:13 EDT High Tide to acquire Jimmy's Cannabis Shop BC for $5.3M - High Tide entered into a definitive agreement pursuant to which High Tide will acquire 100% of the equity interest of 1171882 B.C, operating as Jimmy's Cannabis Shop BC, as well as assignments of the vendors' shareholder loans, resulting in High Tide's acquisition of two of the five retail cannabis stores currently operated by Jimmy's in British Columbia for $5.3M. The Stores are located at 1225 Cranbrook Street North, Cranbrook and 1543 Victoria Street, Prince George.For the trailing four months ended May 31, the stores generated annualized revenue of $5.4M and annualized adjusted EBITDA of $1M. The purchase price represents 5.25x annualized adjusted EBITDA for the trailing four months ended May 31. The transaction, which is an arm's length transaction, is subject to, among other things, receipt of the required approvals from the TSX Venture Exchange and the Liquor and Cannabis Regulation Branch, or BC, and the satisfaction of other customary conditions of closing, and is expected to close in the coming weeks. The consideration for the 100% of equity interest acquired will be $5M and $300,000 for the assignment of $300,000 of the vendors' shareholder loans, all paid in common shares of High Tide on closing on the basis of a deemed price per High Tide Share equal to the 10-day volume weighted average price of the High Tide Shares on the Nasdaq Stock Exchange ending on the trading day that is three business days prior to the closing date, subject to a floor price equal to the Discounted Market Price as of the date this news release hereof. The purchase price represents 5.25x the annualized adjusted EBITDA for the trailing four months ended May 31. From the consideration, an amount equal to $3.7M will be subject to a contractual hold period of four months and one day from the date of closing.

06:05 EDT Axcella Health's AXA1125 shows efficacy in Phase 2b NASH trial - Axcella reported interim results from their ongoing global Phase 2b EMMPACT study to evaluate the safety, tolerability, and efficacy of AXA1125 for the treatment of Nonalcoholic Steatohepatitis, or NASH. These interim results report findings regarding the effects of AXA1125 administration on selected outcome measures after 12- and 24-weeks of treatment. Subjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as measured by FibroScan, a non-invasive measure of liver fibrosis. Subjects with NASH experienced clinically and statistically significant improvements in alanine aminotransferase - ALT -, a measure of liver cell inflammation, at both dose levels of AXA1125. Findings demonstrate improvement in hepatic fat as measured by MRI-PDFF. AXA1125 continues to demonstrate a safe and well tolerated profile. Overall, these positive results confirm AXA1125's multi-targeted impact. Both dose levels are active and will be continued. Consistent with prior clinical trials, T2DM showed results comparable to non-diabetics. Axcella expects to report the topline, 48-week biopsy results in the first half of 2024.

06:05 EDT Galecto reports 'positive' results from ongoing Phase 2a trial of GB2064 - Galecto announced positive results from a planned intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis. Fibrosis is a key disease mechanism of myelofibrosis that destroys the bone marrow function. Reducing fibrosis is required to slow the progression of the disease. Four out of five evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months in the MYLOX-1 trial experienced a greater than or equal to 1-grade reduction in collagen fibrosis of the bone marrow, an improvement suggesting that GB2064 could impact the progression of the disease and be disease modifying.

06:02 EDT Radware expands relationship with Fortune 500 financial services provider - Radware announced it expanded its relationship with a Fortune 500 financial services provider in a multimillion-dollar deal. The multinational industry leader extended its investment in Radware's Application Protection-as-a-Service beyond DDoS protection to include Radware's Cloud Web Application Firewall, API Protection, and Bot Manager. Responsible for its customers' public-facing websites, the financial services provider was under constant cyberattacks. To protect its network and application infrastructure along with the millions of merchants and thousands of financial institutions it supports, the provider turned to Radware to increase its cyber defenses across multiple dimensions, including automation, efficacy, and visibility.

05:51 EDT Lions Gate considers spinning off studio business - In a regulatory filing on Wednesday, Lions Gate Entertainment said" "Despite the volatile market environment, Lions Gate Entertainment Corp. remains on a path to separating our STARZ and studio businesses. As negotiations progress, we have increased our focus on the possibility of spinning our studio business, creating a number of financial and strategic benefits. In that regard, we are continuing productive negotiations with prospective strategic and financial partners on both sides of our business."

05:08 EDT Tradeweb Markets collaborates with S&P Global Market Intelligence - Tradeweb Markets announced its collaboration with S&P Global Market Intelligence to introduce electronic connectivity between primary and secondary markets. The product scope currently includes European credit, covered, sovereign, supranational and agency (SSA) bonds. Tradeweb's integration of InvestorAccess, S&P Global Market Intelligence's digital primary market platform, enables Tradeweb clients to electronically access new deals and manage orders in the primary market via the Tradeweb platform.